Stock since the trade -6.7% · S&P 500 +1.3% · to Oct 1Traded 15 days after results
44K → 42K shares held−3% of their stake
Medtronic's & President Cardiovascular sold $139K of Medtronic shares. Nobody planned it ahead of time.
MDT · NYSE · Health Care Equipment
Health Care Equipment company based in Galway, Ireland.
Last close, Oct 1, 2026
$86.44
Adjusted for splits and dividends
Last 12 months
-8.8%
S&P 500 +14.3% over the same dates
Market value
$111B
Last close × shares outstanding
Bets against the stock: 17.2M shares sold short (1.3% of shares outstanding), +42.0% vs the previous count, 2.0 days of normal trading to buy them back. FINRA, as of Sep 15, 2026.
Insiders buying, last 90 days
None
No open-market purchases reported
Insiders selling, last 90 days
2 sales
$397K sold. Insiders sell for many reasons.
New federal contracts, 12 months
None
Nothing found for this company
Revenue, fiscal 2026
$36.4B
+8.4% vs the year before
Net income, fiscal 2026
$4.8B
As reported in the annual filing
Shares outstanding
1.28B
As of Aug 28, 2026
In fiscal 2026 the company spent $1.03B buying back its own shares and $3.64B on dividends. Cash actually paid, from its cash-flow statement.
Stock since the trade -6.7% · S&P 500 +1.3% · to Oct 1Traded 15 days after results
44K → 42K shares held−3% of their stake
Medtronic's & President Cardiovascular sold $139K of Medtronic shares. Nobody planned it ahead of time.
Officer plans to sell ~$139K of Medtronic
Planned, from pay2 different filers disclosed MDT within 90 days. Disclosed 8 days after the transaction; reported as an official range, not an exact amount.
From a 13F filed Aug 14, 2026 covering holdings at Jun 30, 2026 — a quarter-end snapshot, not a live trade.
3 different filers disclosed MDT within 90 days. Disclosed 15 days after the transaction; reported as an official range, not an exact amount.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Anyone owning more than 5% must file within days. Structured filings exist since December 2024, so older stakes that were never amended may be missing.
Last 12 months, adjusted daily closes
Adjusted close went from $94.81 on Oct 1, 2025 to $86.44 on Oct 1, 2026 (-8.8%). Disclosed trades in the last 12 months: 0 insider purchases, 16 insider sales (1 under pre-arranged plans), 2 Congress purchases, 6 Congress sales.
1 notice filed with state agencies, covering 81 workers in total. Employers must warn the state ahead of a plant closing or mass layoff at a site.
Official WARN lists from California, Texas, New York, Florida, Illinois and Washington only; notices filed in other states are not shown. Matched on the employer name as filed, so a notice filed under an unrelated subsidiary name can be missing. Dates are the notice date (Washington: the date the state received it).
108 certified in FY2026 Q3, vs 125 a year earlier. 108 positions in total, median offered wage $118K a year.
Labor condition applications for H-1B workers certified by the Department of Labor, counted by decision date (FY2026 Q3: Apr 1, 2026 to Jun 30, 2026, the latest quarter published). A certified application is a step before a visa petition, not a hire or a visa, and one application can cover several positions. Matched by employer ID number or name.
50 approvals or clearances and 70 recalls recorded by the FDA for this company and its listed subsidiaries.
From openFDA: Drugs@FDA (new applications and new uses), device 510(k) and PMA decisions, and FDA enforcement reports. Class I recalls are the most serious, Class III the least. Most recalls are started by the company itself. Labeling and manufacturing changes are not listed.
Top officer leaving
“Compensatory Arrangements of Certain Officers On May 18, 2026, Medtronic plc (“Medtronic” or the “Company”) announced that Brett Wall will be departing from his position as Executive Vice President and President, Neuroscience Portfolio, and that Dr.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Short sale volume: 48.6% of the volume reported to FINRA over the last 20 trading days was marked short, above its 1-year average of 38.8%. FINRA daily files, to Oct 2, 2026.
Fails to deliver: 26K shares (about $2.41M) were not delivered on time for settlement on Sep 11, 2026. SEC fails-to-deliver data.
Short sale volume is not short interest. It counts trades marked short, including market makers selling short to fill buy orders, so it is a share of daily trading, not a count of bets against the stock. Fails to deliver have many causes, including processing delays, and are often resolved within days.